{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:53:40Z","timestamp":1790790820558,"version":"4.1.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.clinthera.2013.04.001","type":"journal-article","created":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T12:07:48Z","timestamp":1367410068000},"page":"548-562","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["Expanding Spectrum of Mast Cell Activation Disorders: Monoclonal and Idiopathic Mast Cell Activation Syndromes"],"prefix":"10.1016","volume":"35","author":[{"given":"Matthieu","family":"Picard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Giavina-Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Mezzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2013.04.001_bib1","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jaci.2010.06.022","article-title":"The diagnosis and management of anaphylaxis practice parameter: 2010 update","volume":"126","author":"Lieberman","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2013.04.001_bib2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000328760","article-title":"Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal","volume":"157","author":"Valent","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.clinthera.2013.04.001_bib3","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.clinthera.2013.04.001_bib4","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jaci.2010.08.035","article-title":"Mast cell activation syndrome: proposed diagnostic criteria","volume":"126","author":"Akin","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2013.04.001_bib5","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood-2007-11-078097","article-title":"Mast cells and mastocytosis","volume":"112","author":"Metcalfe","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2013.04.001_bib6","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/blood-2006-06-028100","article-title":"Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with \u201cidiopathic\u201d anaphylaxis","volume":"110","author":"Akin","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2013.04.001_bib7","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jaci.2008.11.018","article-title":"Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels","volume":"123","author":"Bonadonna","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2013.04.001_bib8","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jaci.2010.02.019","article-title":"Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms","volume":"125","author":"Alvarez-Twose","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2013.04.001_bib9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000329856","article-title":"Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms","volume":"157","author":"Alvarez-Twose","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.clinthera.2013.04.001_bib10","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000096442","article-title":"Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: monoclonal mast cell activation syndrome","volume":"142","author":"Sonneck","year":"2007","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.clinthera.2013.04.001_bib11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jaci.2011.04.037","article-title":"Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations","volume":"128","author":"Hamilton","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2013.04.001_bib12","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000048188","article-title":"Mastocytosis: mediator-related signs and symptoms","volume":"127","author":"Castells","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2013.04.001_bib13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1365-2249.2008.03714.x","article-title":"Allergy and the cardiovascular system","volume":"153","author":"Triggiani","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.clinthera.2013.04.001_bib14","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1160\/TH11-05-0351","article-title":"Bleeding diathesis in patients with mast cell activation disease","volume":"106","author":"Seidel","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clinthera.2013.04.001_bib15","doi-asserted-by":"crossref","first-page":"7834","DOI":"10.1074\/jbc.M111.325712","article-title":"Mast cell restricted mouse and human tryptase\/heparin complexes hinder thrombin-induced coagulation of plasma and the generation of fibrin by proteolytically destroying fibrinogen","volume":"287","author":"Prieto-Garcia","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2013.04.001_bib16","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJM200208223470820","article-title":"Bradykinin-mediated angioedema","volume":"347","author":"Nussberger","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2013.04.001_bib17","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11882-012-0326-8","article-title":"Immunology and clinical manifestations of non-clonal mast cell activation syndrome","volume":"13","author":"Cardet","year":"2013","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.clinthera.2013.04.001_bib18","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2005.03.038","article-title":"Current status of gastrointestinal carcinoids","volume":"128","author":"Modlin","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2013.04.001_bib19","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1056\/NEJM197902013000506","article-title":"Blockade of the flush associated with metastatic gastric carcinoid by combined histamine H1 and H2 receptor antagonists","volume":"300","author":"Roberts","year":"1979","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2013.04.001_bib20","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/ki.1991.244","article-title":"Pheochromocytoma: new concepts and future trends","volume":"40","author":"Bravo","year":"1991","journal-title":"Kidney Int"},{"key":"10.1016\/j.clinthera.2013.04.001_bib21","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1365-2265.2007.02805.x","article-title":"The diagnostic efficacy of urinary fractionated metanephrines measured by tandem mass spectrometry in detection of pheochromocytoma","volume":"66","author":"Perry","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.clinthera.2013.04.001_bib22","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.seminoncol.2012.11.009","article-title":"Update on the management of unusual neuroendocrine tumors: pheochromocytoma and paraganglioma, medullary thyroid cancer and adrenocortical carcinoma","volume":"40","author":"Strosberg","year":"2013","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clinthera.2013.04.001_bib23","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S0025-6196(11)61027-6","article-title":"Postural orthostatic tachycardia syndrome: the Mayo clinic experience","volume":"82","author":"Thieben","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clinthera.2013.04.001_bib24","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1161\/01.HYP.0000158259.68614.40","article-title":"Hyperadrenergic postural tachycardia syndrome in mast cell activation disorders","volume":"45","author":"Shibao","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2013.04.001_bib25","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/BF01533368","article-title":"Development of a new, more sensitive immunoassay for human tryptase: use in systemic anaphylaxis","volume":"14","author":"Schwartz","year":"1994","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.clinthera.2013.04.001_bib26","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1006\/meth.1997.0494","article-title":"Markers of mast cell degranulation","volume":"13","author":"Hogan","year":"1997","journal-title":"Methods"},{"key":"10.1016\/j.clinthera.2013.04.001_bib27","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/0091-6749(94)90371-9","article-title":"Detection of the major urinary metabolite of prostaglandin D2 in the circulation: demonstration of elevated levels in patients with disorders of systemic mast cell activation","volume":"93","author":"Awad","year":"1994","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2013.04.001_bib28","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000144042","article-title":"Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D(2) production","volume":"147","author":"Butterfield","year":"2008","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.clinthera.2013.04.001_bib29","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11882-012-0315-y","article-title":"Delayed anaphylaxis to red meat in patients with IgE specific for galactose alpha-1,3-galactose (alpha-gal)","volume":"13","author":"Commins","year":"2013","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.clinthera.2013.04.001_bib30","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/ajh.23380","article-title":"Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chromosomal abnormalities in SM and AHNMD components","volume":"88","author":"Wang","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clinthera.2013.04.001_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000336374","article-title":"Evaluation of mast cell activation syndromes: impact of pathology and immunohistology","volume":"159","author":"Horny","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.clinthera.2013.04.001_bib32","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jaci.2009.10.020","article-title":"Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes","volume":"125","author":"Teodosio","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2013.04.001_bib33","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/jid.2009.281","article-title":"Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations","volume":"130","author":"Bodemer","year":"2010","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clinthera.2013.04.001_bib34","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/11588890-000000000-00000","article-title":"Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations","volume":"12","author":"Castells","year":"2011","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clinthera.2013.04.001_bib35","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.hoc.2012.08.001","article-title":"Systemic mastocytosis: disease overview, pathogenesis, and treatment","volume":"26","author":"Pardanani","year":"2012","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clinthera.2013.04.001_bib36","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2217\/imt.11.44","article-title":"Venom immunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis","volume":"3","author":"Gonzalez-de-Olano","year":"2011","journal-title":"Immunotherapy"},{"key":"10.1016\/j.clinthera.2013.04.001_bib37","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/ACI.0b013e32833b280c","article-title":"Mastocytosis and insect venom allergy","volume":"10","author":"Bonadonna","year":"2010","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2013.04.001_bib38","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jaci.2007.11.010","article-title":"Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis","volume":"121","author":"Gonzalez de Olano","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2013.04.001_bib39","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jaci.2007.10.014","article-title":"Allergen specific immunotherapy is safe and effective in patients with systemic mastocytosis and Hymenoptera allergy","volume":"121","author":"Bonadonna","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2013.04.001_bib40","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1398-9995.2007.01604.x","article-title":"High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis","volume":"63","author":"Kontou-Fili","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.clinthera.2013.04.001_bib41","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/ACI.0b013e328355b7cb","article-title":"Drug allergy in mast cell disease","volume":"12","author":"Brockow","year":"2012","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2013.04.001_bib42","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0091-6749(83)90098-2","article-title":"Intervention with epinephrine in hypotension associated with mastocytosis","volume":"71","author":"Turk","year":"1983","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2013.04.001_bib43","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11882-009-0080-8","article-title":"Anaphylaxis and mast cell disease: what is the risk?","volume":"10","author":"Akin","year":"2010","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.clinthera.2013.04.001_bib44","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMra033121","article-title":"Advances in H1-antihistamines","volume":"351","author":"Simons","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2013.04.001_bib45","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0889-8588(05)70301-4","article-title":"Treatment of systemic mast cell disorders","volume":"14","author":"Worobec","year":"2000","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clinthera.2013.04.001_bib46","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/0091-6749(89)90097-3","article-title":"A double-blind, placebo-controlled, crossover trial of ketotifen versus hydroxyzine in the treatment of pediatric mastocytosis","volume":"83","author":"Kettelhut","year":"1989","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2013.04.001_bib47","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000249832","article-title":"A double-blind cross-over study of the effect of ketotifen in urticaria pigmentosa","volume":"166","author":"Czarnetzki","year":"1983","journal-title":"Dermatologica"},{"key":"10.1016\/j.clinthera.2013.04.001_bib48","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2796.1991.tb00379.x","article-title":"A case of systemic mastocytosis; therapeutic efficacy of ketotifen","volume":"229","author":"Povoa","year":"1991","journal-title":"J Intern Med"},{"key":"10.1016\/j.clinthera.2013.04.001_bib49","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000247526","article-title":"Systemic mastocytosis treated with histamine H1 and H2 receptor antagonists","volume":"184","author":"Gasior-Chrzan","year":"1992","journal-title":"Dermatology"},{"key":"10.1016\/j.clinthera.2013.04.001_bib50","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0002-9343(85)90454-1","article-title":"Comparison of the therapeutic efficacy of cromolyn sodium with that of combined chlorpheniramine and cimetidine in systemic mastocytosis","volume":"78","author":"Frieri","year":"1985","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2013.04.001_bib51","first-page":"485","article-title":"Long-term treatment of systemic mastocytosis with histamine H2 receptor antagonists","volume":"74","author":"Johnson","year":"1980","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2013.04.001_bib52","doi-asserted-by":"crossref","first-page":"769","DOI":"10.7326\/0003-4819-90-5-769","article-title":"Effect of cimetidine on gastric hypersecretion and diarrhea in systemic mastocytosis","volume":"90","author":"Hirschowitz","year":"1979","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2013.04.001_bib53","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1056\/NEJM197908303010903","article-title":"Oral disodium cromoglycate in the treatment of systemic mastocytosis","volume":"301","author":"Soter","year":"1979","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2013.04.001_bib54","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/0091-6749(90)90067-E","article-title":"Cromolyn sodium in the management of systemic mastocytosis","volume":"85","author":"Horan","year":"1990","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2013.04.001_bib55","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1365-2222.1992.tb03102.x","article-title":"Inhibition profiles of sodium cromoglycate and nedocromil sodium on mediator release from mast cells of human skin, lung, tonsil, adenoid and intestine","volume":"22","author":"Okayama","year":"1992","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.clinthera.2013.04.001_bib56","doi-asserted-by":"crossref","first-page":"e33805","DOI":"10.1371\/journal.pone.0033805","article-title":"Quercetin is more effective than cromolyn in blocking human mast cell cytokine release and inhibits contact dermatitis and photosensitivity in humans","volume":"7","author":"Weng","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2013.04.001_bib57","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/j.1365-2133.2009.09516.x","article-title":"Topical sodium cromoglicate relieves allergen- and histamine-induced dermal pruritus","volume":"162","author":"Vieira Dos Santos","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clinthera.2013.04.001_bib58","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJM200402123500723","article-title":"Leukotriene-receptor inhibition for the treatment of systemic mastocytosis","volume":"350","author":"Tolar","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2013.04.001_bib59","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1525-1470.2011.01576.x","article-title":"Refractory symptoms successfully treated with leukotriene inhibition in a child with systemic mastocytosis","volume":"29","author":"Turner","year":"2012","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.clinthera.2013.04.001_bib60","first-page":"513","article-title":"Recent-onset bronchial asthma as a manifestation of systemic mastocytosis","volume":"19","author":"Sancho-Chust","year":"2009","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.clinthera.2013.04.001_bib61","doi-asserted-by":"crossref","first-page":"481","DOI":"10.4065\/70.5.481","article-title":"Aspirin idiosyncrasy in systemic mast cell disease: a new look at mediator release during aspirin desensitization","volume":"70","author":"Butterfield","year":"1995","journal-title":"Mayo Clin Proc"},{"issue":"8672","key":"10.1016\/j.clinthera.2013.04.001_bib62","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(89)91516-X","article-title":"Aspirin and systemic mastocytosis","volume":"2","author":"Lorcerie","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2013.04.001_bib63","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.anai.2012.02.021","article-title":"Prevention of anaphylaxis related to mast cell activation syndrome with omalizumab","volume":"108","author":"Bell","year":"2012","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.clinthera.2013.04.001_bib64","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2169\/internalmedicine.50.4640","article-title":"Omalizumab treatment of systemic mast cell activation disease: experiences from four cases","volume":"50","author":"Molderings","year":"2011","journal-title":"Intern Med"},{"key":"10.1016\/j.clinthera.2013.04.001_bib65","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.jaci.2006.04.005","article-title":"Anti-IgE as a mast cell-stabilizing therapeutic agent","volume":"117","author":"Chang","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2013.04.001_bib66","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/ejh.12043","article-title":"Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression","volume":"90","author":"Verstovsek","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clinthera.2013.04.001_bib67","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s10238-006-0114-7","article-title":"Inhibitory effect of quercetin on tryptase and interleukin-6 release, and histidine decarboxylase mRNA transcription by human mast cell-1 cell line","volume":"6","author":"Kempuraj","year":"2006","journal-title":"Clin Exp Med"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291813001719?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291813001719?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:48:59Z","timestamp":1758962939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291813001719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":67,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0149291813001719"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2013.04.001","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expanding Spectrum of Mast Cell Activation Disorders: Monoclonal and Idiopathic Mast Cell Activation Syndromes","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2013.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier HS Journals, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}